2020
Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non–small cell lung cancer: A network meta‐analysis of randomized trials
Pathak R, De Lima Lopes G, Yu H, Aryal MR, Ji W, Frumento KS, Wallis CJD, Klaassen Z, Park HS, Goldberg SB. Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non–small cell lung cancer: A network meta‐analysis of randomized trials. Cancer 2020, 127: 709-719. PMID: 33119177, DOI: 10.1002/cncr.33269.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerAdvanced non-small cell lung cancerSingle-agent ICICell lung cancerPD-L1Lung cancerAdditional overall survival benefitsEfficacy of chemoimmunotherapyFirst-line ICIHigh PD-L1Overall survival benefitCochrane Central RegisterFirst-line treatmentPD-L1 statusPhase 3 trialLow PD-L1Absence of headSignificant differencesRandom-effects modelBayesian random-effects modelImproved PFSOS benefitEfficacy outcomesEligible trialsCentral Register
2014
Prophylactic Cranial Irradiation for Patients With Locally Advanced Non–Small-Cell Lung Cancer at High Risk for Brain Metastases
Park HS, Decker RH, Wilson LD, Yu JB. Prophylactic Cranial Irradiation for Patients With Locally Advanced Non–Small-Cell Lung Cancer at High Risk for Brain Metastases. Clinical Lung Cancer 2014, 16: 292-297. PMID: 25499149, DOI: 10.1016/j.cllc.2014.11.005.Peer-Reviewed Original ResearchConceptsProphylactic cranial irradiationLA-NSCLC patientsSequential landmark analysesCell lung cancerBrain metastasesHigh riskCranial irradiationSurvival benefitLung cancerLandmark analysisEffect of PCICox proportional hazards regressionNon-PCI patientsOverall survival benefitEnd Results (SEER) databaseHigh-risk patientsStage III NSCLCGroup of patientsProportional hazards regressionLog-rank testSignificant survival differenceImmortal time biasPopulation-based analysisAdult patientsOnly patients